CytoSorb infectious data

A post hoc analysis of 14 septic patients with elevated levels of IL-6 (>=1,000 pg/mL) or IL-1 receptor antagonist ( IL-1RA) (>=16,000 pg/mL) from the European Sepsis Trial showed that CytoSorb plus standard of care (SOC) significantly reduced 28-day all-cause mortality vs. SOC alone (0% vs. 62.5%, p=0.03). CytoSorb plus SOC non-significantly reduced 60-day all-cause mortality vs. SOC alone (16.7% vs. 62.5%, p=0.14). The company said it now plans to conduct a small clinical trial in patients with high levels of either IL-6 or IL-1RA to confirm the results. ...